--- title: "NKGen Biotech Secures Additional Convertible Financing and Warrants" type: "News" locale: "en" url: "https://longbridge.com/en/news/285133504.md" description: "NKGen Biotech has amended its secured convertible loan agreement with AlpineBrook Capital, securing an additional $607,200 convertible loan with a conversion price of $0.08 per share. The deal includes 12,009,780 consideration shares, a new secured convertible note, and a 10-year warrant. A voting agreement with shareholders aims to increase authorized common shares for potential conversions and warrant exercises. This financing may increase dilution for existing shareholders and reflects NKGen's reliance on equity-capital structures for funding. NKGen Biotech focuses on developing therapies using proprietary NK cell technologies." datetime: "2026-05-04T23:16:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285133504.md) - [en](https://longbridge.com/en/news/285133504.md) - [zh-HK](https://longbridge.com/zh-HK/news/285133504.md) generator: "portal-rs" --- # NKGen Biotech Secures Additional Convertible Financing and Warrants ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks NKGen Biotech ( (NKGN) ) has provided an announcement. On April 28, 2026, NKGen Biotech and its subsidiary NKGen Operating Biotech amended their secured convertible loan agreement with AlpineBrook Capital, securing an additional $607,200 convertible loan that yields $552,000 in net proceeds and carries a conversion price of $0.08 per share. As part of the deal, NKGen increased the consideration shares to 12,009,780, issued a new secured convertible note and a 10-year warrant with a 9.99% ownership cap and anti-dilution protections, and entered into a voting agreement with key shareholders to support an increase in authorized common shares to accommodate potential conversions and warrant exercises, all executed as unregistered offerings under Securities Act exemptions. The additional financing and equity-linked incentives deepen AlpineBrook’s economic exposure while potentially increasing future dilution for existing shareholders. The voting agreement and required shareholder approval for a larger share pool underscore NKGen’s reliance on equity-capital structures to support its funding needs and may influence its capital structure and control dynamics as subsequent financings close. **More about NKGen Biotech** NKGen Biotech, Inc. is a Delaware-based biotechnology company focused on developing therapies using its proprietary natural killer (NK) cell technologies. The company operates through its wholly owned subsidiary NKGen Operating Biotech, Inc. and targets capital-raising arrangements that often involve convertible debt and equity-linked securities to fund its operations and growth in the biotech sector. **Average Trading Volume:** 5,100 **Technical Sentiment Signal:** Sell **Current Market Cap:** $7.84M Learn more about NKGN stock on TipRanks’ Stock Analysis page. ### Related Stocks - [NKGN.US](https://longbridge.com/en/quote/NKGN.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [NKGNW.US](https://longbridge.com/en/quote/NKGNW.US.md) ## Related News & Research - [NKGen Biotech amends convertible loan deal with AlpineBrook, adds USD 1.05 million note](https://longbridge.com/en/news/297830645.md) - [3 healthcare ETFs to own in a choppy stock market](https://longbridge.com/en/news/291834343.md) - [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md) - [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md) - [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**